NHS England releases draft Commercial Framework
NHS England has released a consultation draft of its new Commercial Framework, agreed as part of the UK’s 2019 Voluntary … read more »
Access to cancer drugs and IFRs in Northern Ireland
The Department of Health in Northern Ireland has announced that it has agreed to change the availability of cancer drugs … read more »
NICE rejects Opdivo for adjuvant treatment of melanoma on NHS
The National Institute for Clinical and Healthcare Excellence (NICE) has released its draft appraisal consultation document (ACD), rejecting the use … read more »
Novartis CAR-T Kymriah to come to the NHS
NHS England (NHSE) have reached an agreement to reimburse Novartis’s CAR-T therapy Kymriah (tisagenlecleucel) for patients up to 25 years of age … read more »
New Cancer Drugs Fund benefiting thousands and adding £140million for the NHS
Since the opening of the reformed Cancer Drugs Fund (CDF) in July 2016 thousands of patients have benefited from accelerated … read more »
Cancer Drugs Fund Poor Value for Money, Study Finds
England’s Cancer Drugs Fund (CDF) is poor value for money and may be exposing patients to unnecessary harm, concludes new … read more »
NICE Says Patients Accessing More Cancer Drugs Following Price Drops
The cancer drugs fund (CDF) transitioned to a new model last July (see our CDF page on MAP for more detail). All treatments … read more »
Cancer Drugs May be Delayed after Brexit
Former UK regulator Sir Alasdair Breckenridge warned that patients could face delays getting new drugs if Britain withdraws from the … read more »
NICE Approves Three Quarters of CDF Group 1 Drugs for Routine Use
Drugs previously funded through the cancer drugs fund (CDF) have been going through a reappraisal process by NICE ever since … read more »
NICE Request Case for Including Nivolumab (Opdivo, Bristol-Myers Squibb) in the Cancer Drugs Fund (CDF)
NICE has asked Bristol-Myers Squibb to set out its case for including nivolumab (Opdivo, Bristol-Myers Squibb) in the Cancer Drugs … read more »
